Findings

What do systematic reviews say?

34 questions · 34 findings · 7 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 2.9%GRADE not reported 3 · 8.8%Very low 0 · 0%Low 12 · 35.3%Moderate 5 · 14.7%High 13 · 38.2%

Intervention not reported

Adverse events · patients with idiopathic inflammatory myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 37 participants
GRADE not reported

Intervention not reported

Maximum voluntary contraction in myotonic dystrophy type 1 % · patients with muscular dystrophies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 76 participants
Moderate

Intervention not reported

Maximum voluntary contraction in myotonic dystrophy type 2 % · patients with muscular dystrophies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
High

Intervention not reported

Adverse events · patients with muscular dystrophies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 261 participants
High

Intervention not reported

Global assessment of improvement felt better · patients with muscular dystrophies

The intervention leads to higher global assessment of improvement felt better (high certainty).

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
RR 4.51 [2.33, 8.74]
4 studies · 183 participants
High

Intervention not reported

Maximum voluntary contraction in mitochondrial diseases % · patients with metabolic myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 38 participants
High

Intervention not reported

Maximum voluntary contraction in glycogen storage disease type V % · patients with metabolic myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 28 participants
High

Intervention not reported

Impairment of activities of daily living (ADL) in glycogen storage disease type V Visual numeric scale. Scale from: 1 to 10. · patients with metabolic myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 19 participants
High

Intervention not reported

Adverse events in mitochondrial diseases · patients with metabolic myopathies

1 finding from 1 review

Creatine for treating muscle disorders 2013 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 38 participants
GRADE not reported

Intervention not reported

Tracheostomy‐free survival · patients with amyotrophic lateral sclerosis

1 finding from 1 review

Creatine for amyotrophic lateral sclerosis/motor neuron disease 2012 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 386 participants
High

Intervention not reported

ALSFRS‐R slope Change in ALSFRS‐R / month · patients with amyotrophic lateral sclerosis

1 finding from 1 review

Creatine for amyotrophic lateral sclerosis/motor neuron disease 2012 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 386 participants
High

Intervention not reported

FVC Slope Change in FVC / month · patients with amyotrophic lateral sclerosis

1 finding from 1 review

Creatine for amyotrophic lateral sclerosis/motor neuron disease 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 211 participants
High

Intervention not reported

Creatinine phosphate 1g/day for 6 months · patients with heart failure

1 finding from 1 review

Creatine and creatine analogues in hypertension and cardiovascular disease 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 79 participants
Low

Intervention not reported

Creatinine phosphate 1g/day for 3 months · patients with heart failure

1 finding from 1 review

Creatine and creatine analogues in hypertension and cardiovascular disease 2011 · Cochrane Headline outcomes only
no estimate extracted
1 study · 88 participants
Low